Jefferies Downgrades Aerovate Therapeutics to Hold, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Eun Yang has downgraded Aerovate Therapeutics (NASDAQ:AVTE) from Buy to Hold and significantly lowered the price target from $65 to $2.
June 17, 2024 | 6:23 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Jefferies analyst Eun Yang downgraded Aerovate Therapeutics from Buy to Hold and drastically reduced the price target from $65 to $2.
The downgrade from Buy to Hold and the significant reduction in the price target from $65 to $2 by Jefferies is likely to negatively impact investor sentiment and the stock price of Aerovate Therapeutics in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100